In short
Clinical trials are investigating Vx-670 in people with myotonic dystrophy type I (DM1). These studies are looking mainly at safety, tolerability, and early signs of benefit in adult patients. The trials include phase 1 and phase 1/2 research with intravenous treatment.
Key points
- Clinical trials of Vx-670 are being done in people with myotonic dystrophy type I, a muscle disease. The studies are early-stage, with one phase 1 trial and one phase 1/2 trial. One trial looks at long-term safety and tolerability, while the other studies single and multiple ascending doses. Both trials focus on adult patients and use intravenous administration. The main outcomes are safety checks such as adverse events, vital signs, ECGs, lab tests, and a suicide severity rating scale in one study.
Clinical trial overview
The available studies are investigating Vx-670 in people with myotonic dystrophy type I (DM1), which is the condition named in the trial records. Both studies are interventional, meaning researchers give the study treatment and then measure what happens. The two trials are both listed as Authorised.
Who the studies include
The trial data show that the studies are focused on adult subjects with DM1. One trial is described as long-term safety and efficacy research in patients with DM1, while the other is a phase 1/2 study in adult subjects with DM1. Based on the source data, the target population is people living with this specific muscle disease, not the general public.
How the trials are designed
One study is a Phase 1 trial with 39 enrolled participants. The other is a Phase 1/2 trial with 44 enrolled participants. These are early-stage studies, which usually help researchers learn about safety first and then look for early signs of benefit.
The phase 1/2 study has two parts. Part A evaluates single ascending doses, which means one dose is given and then the dose level is increased in later groups if the study allows it. Part B evaluates single and multiple ascending doses, which means researchers study both one-time dosing and repeated dosing at increasing levels.
Both studies use intravenous administration, meaning the treatment is given through a vein. In the phase 1/2 trial, a comparison treatment of 0.9% saline solution is also listed.
What the trials measure
The main goal in both trials is to assess safety and tolerability of Vx-670. Safety means whether the treatment causes medical problems, and tolerability means how well people can take it without major difficulty.
In the phase 1 study, safety and tolerability are checked using adverse events, vital signs, electrocardiograms (ECGs), and clinical laboratory values. In the phase 1/2 study, the same safety focus is used, and the measures include adverse events, laboratory test results, standard 12-lead ECGs, vital signs, and the Columbia Suicide Severity Rating Scale (C-SSRS).
The brief summary of the phase 1/2 trial says it also aims to evaluate safety and tolerability in both single and multiple ascending dose settings, which helps researchers learn how people respond across different exposure patterns. The long-term study is specifically described as evaluating long-term safety and tolerability in subjects with DM1.
Trial-by-trial summary
- 2024-517983-47-00: A phase 1 study in 39 people with DM1, focused on long-term safety and tolerability of Vx-670.
- 2023-506028-10-00: A phase 1/2 study in 44 adult subjects with DM1, studying single and multiple ascending doses and safety outcomes.
Patient-friendly terms
Adverse events are unwanted health problems that happen during a study, whether or not the treatment caused them. ECG is a heart test that records electrical activity and helps researchers watch for heart changes. Laboratory values are results from blood or other lab tests that help show how the body is doing.
Vital signs are basic body checks such as blood pressure, pulse, temperature, and breathing rate. Tolerability means how well a person can handle the study treatment without major problems. Long-term means the study follows people over a longer period to look for effects that may not show up right away.